Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

BARCELONA, Spain, Nov. 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that its investigational medicine canagliflozin substantially lowered blood glucose levels compared to placebo when used as add-on therapy in patients with type 2 diabetes who are inadequately controlled with the antihyperglycemic medications metformin and pioglitazone. These results were presented at the 4th World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy). 

The data presented are the latest Phase 3 results for canagliflozin, which is being evaluated across a spectrum of patients with type 2 diabetes. Results from the study (known as DIA3012) showed that canagliflozin, dosed once daily at 100 mg or 300 mg in addition to metformin and pioglitazone, had statistically greater A1C reductions at 26 weeks relative to placebo (change from baseline, -0.89% and -1.03%, vs. -0.26%, respectively, p<0.001). The overall incidence of adverse events (AEs) was generally similar across all treatment arms.

"Given the global diabetes epidemic and the significant burden faced by patients who suffer from uncontrolled diabetes, it is critical that we evaluate new therapies in combination with existing antihyperglycemic therapies," said Dr. Thomas Forst, lead investigator on the study from the University of Mainz in Mainz, Germany. "The efficacy and safety profile for canagliflozin in this trial is encouraging. This data combined with other results seen to date, show that canagliflozin may provide added benefit in managing important diabetes parameters when used alone or in addition to existing diabetes treatments."

In secondary efficacy endpoint measures of the study, both the canagliflozin 100 mg and 300 mg dose groups provided reductions in body weight compared to placebo (-2.8% and -3.8% vs. -0.1%, respectively, p<0.001) and reductions in systolic blood pressure (-5.3 mmHg, p<0.01 and -4
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... Nov. 4 CVS Caremark (NYSE: CVS ) ... position of SVP, Marketing for its pharmacy benefit management ... marketing from Jack Bruner, who is transitioning to the ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings ...
... 4 Neuronascent, Inc., a privately-held biotechnology company ... of depression, Alzheimer,s disease, Parkinson,s and other neurodegenerative ... agreement with ChemRar Pharma, a Russian biotechnology start-up ... and stem cells to treat cancer. Under the ...
Cached Medicine Technology:Company Appoints New SVP, Marketing for PBM Business 2Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform 2
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Emergency Medical ... urgent care in Manhattan, recently commemorated its three-year anniversary ... in Manhattan. In addition to 24-hour urgent care, Emergency ... , At this time, Emergency Medical Care’s ... pain, asthma, chest pain, eye injuries, ear infections, fevers, ...
(Date:3/28/2015)... IL (PRWEB) March 28, 2015 Centurion Service ... equipment auction on Thursday, April 2 at their Las Vegas ... Vegas, NV 89081. The sale, which consists of equipment from ... begin promptly at 9 a.m. PDT. , Buyers will ... and surgery equipment. “We are a one-stop-shop,” said Erik Tivin, ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... the $60 billion international beauty products industry is ... a hundred cosmetics are in the Project on ... manufacturers as containing nanomaterials. , Critical to ... in their safety. In Europe, regulators and companies ...
... The rate of childhood,obesity in America has ... percent of children ages 10 to 17 are ... threat of the obesity epidemic for,children, families, communities ... a Healthy Florida ( http://www.bluefoundationfl.com ), the,philanthropic affiliate ...
... Joins 40 Others in Screening for Life-Threatening, Genetic,Disease, ... and the District of Columbia in requiring that all ... congratulate Alabama for initiating a newborn screening program for,cystic ... of the,Cystic Fibrosis Foundation. "More than 40 states are ...
... the Number of Women,s ... Medications Offered at a Discount, CINCINNATI, May 13 ... will expand their generic drug,program -- offering customers lower prices ... is offering 90-day prescriptions for,only $10 on its expanded generic ...
... Ancient acupuncture and modern myofascial pain therapy each focus ... treat pain, although they do it differently, says a ... two techniques. , Results of the study, published May ... suggest that people who want relief from chronic musculoskeletal ...
... New Retinoic Acid and Clindamycin Products Developed ... Skinvisible, Inc. (OTC,Bulletin Board: SKVI) ( ... on formulating enhanced patented dermatology,products, announced it ... Pharmaceutical Co. Ltd. ("Embil"). The Agreement is ...
Cached Medicine News:Health News:The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity 2Health News:Alabama Begins Mandatory Screening of Newborns for Cystic Fibrosis 2Health News:Kroger and Its Family of Stores Expand Discounted Generic Drug Program 2Health News:Kroger and Its Family of Stores Expand Discounted Generic Drug Program 3Health News:Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas 2Health News:Skinvisible Signs Licensing Agreement for Two Acne Formulations 2Health News:Skinvisible Signs Licensing Agreement for Two Acne Formulations 3
... Analyzer II is a ... to enumerate fluorescently labeled ... selected and aligned. The ... CellTracks® Analyzer II, a ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: